Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors.

"Disclosure D.L. reports research funding to his institution from AstraZeneca and Brooklyn ImmunoTherapeutics. He serves as a consultant and has received honoraria from Adagene, Advanced Accelerator Applications, Coherus BioSciences, Eisai, Exelixis, Genentech, Ipsen Biopharmaceuticals, Lexicon Pharmaceuticals, Merck, MiNA Therapeutics, QED Therapeutics, Servier, Sun Pharma, TerSera Therapeutics, and Delcath. A.C. reports research support from Bristol Myers Squibb, Clovis, Nanotherapeutics, TerSera Therapeutics, Lexicon Pharmaceuticals, and ECS Progastrin. He has served as an advisor to TerSera Therapeutics, Lexicon Pharmaceuticals, Novartis, Ipsen, and Crinetics. C.D., L.J. and D.G. are employees of RTI Health Solutions which received research funding for this study from TerSera Therapeutics. S.S., J.C., and N.O. are employees and shareholders of TerSera Therapeutics. The authors report no other conflicts of interest in this work."

"This research was funded by TerSera Therapeutics."